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Abstract
This review article summarizes the issues concerning the pathogenesis of Crohn’s disease (CD) based on the results of 
large-scale genome-wide association studies. The role of defects in innate immunity associated with mutations in specific genes 
such as those regulating bacterial pattern recognition (NOD2/CARD15) and autophagy/xenophagy (ATG16L1 and IRGM) in CD 
is also discussed. Basic pathogenetic hypotheses that aim to interpret the association between specific gene mutations and CD 
development are presented. 
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Introduction
Crohn’s disease (CD) is a multisystemic disease 
with unknown etiology and is characterized by nonspecific 
granulomatous  transmural  inflammation  with  segmented 
injuries in any part of the gastrointestinal tract (GIT) [1, 2]. 
Epidemiological data shows that the incidence and prevalence 
of CD in northern Europe and North America have increased, 
which also has major social impact [3, 4]. In last decades, the 
significant  increase  in  understanding  of  molecular  genetics 
of  CD,  allowed  the  identification  of  genetic  determinants 
associated with CD pathology [2, 5]. 
The results of various epidemiological studies have 
identified the role of genetic factors in the pathogenesis of CD. 
In particular, several observations provide evidence that this 
specific pathology commonly occurs in families of patients 
with CD [1, 2, 6, 7]. Approximately one of every five patients 
with CD has at least one relative with the same pathology 
[8]. However, in studies involving monozygotic twins, a 
67% concordance (comorbidity in both twins) has been 
demonstrated for CD [2]. In addition, the ethnic variations in 
CD incidence rate are in favor of a genetic component in its 
pathogenesis. For example, the CD incidence rate is 2–4 times 
higher in Eastern Europe, with the exception of the Ashkenazi 
Jews and other ethnic groups [9]. Therefore, the enumerated 
factors  serve  as  prerequisites  for  the  identification  of  CD 
susceptible loci. 
The evolution of molecular genetic technologies 
has resulted in a new epoch of genome-wide association 
studies  (GWAS),  which  facilitates  in  the  identification  of 
the new candidate genes for CD based on their genomic 
localization, without reference to its biological effect or mode 
of inheritance [10]. GWAS have become the all-powerful 
catalyst in understanding the pathogenesis of CD, resulting 
in the identification of approximately more than 30 loci that 
confer a predisposition to CD [11, 12]. The most associations 
between CD and specific mutations include those regulating 
the bacterial pattern recognition and autophagy [2, 6, 13].
NOD2/CARD15. A first susceptibility locus identified 
for CD is NOD2, also known as CARD15; this gene was 
identified by two independent research groups in early 2001 
[14,15]. This particular investigation could be considered 
as  the  most  significant  achievement  in  genetic  studies  of 
inflammatory bowel diseases [1,5].
NOD2/CARD15 encodes for the cytosolic protein, 
NOD2, which is an intracellular pattern-recognizing receptor 
binding to muramyl dipeptide (MDP) [16,17]. The last one 
is the component of bacterial peptidoglycan from walls of 
Gram-positive and Gram-negative bacteria [17]. NOD2 is 
preferentially expressed in immunocompetent cells such as 
macrophages, dendritic cells, and Paneth cells [18]. Paneth 
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cells are specialized cells of the small intestines that produce 
antibacterial substances called α-defensins [19].
NOD2 consists of two CARD domains, one nucleotide 
binding domain (NBD), and a leucine-rich repeat region 
(LRR), which serves as the domain for MDP recognition [20]. 
Pattern recognition by NOD2 is associated with activation 
of signal transduction, which results in the induction of the 
transcription  factor,  NF-κB.  Its  activation  results  in  the 
transcription of several pro-inflammatory genes [17, 21, 22]. 
NOD2 is the most important component of innate immunity, 
which subsequently confirms the hypothesis that an alteration 
in the immune response to gastrointestinal microbiota 
influences the development of CD [2].
At least 30 alleles of NOD2/CARD15  have been 
identified [23]. However, the most frequent allele variants in 
European and American populations that are associated with 
CD include two missense mutations, Arg702Trp, Gly908Arg, 
and a frameshift mutation Leu1007fsinsC [2, 6, 13-15]. These 
particular mutations represent 82% of all NOD2/CARD15 
gene variations that have been associated with CD [24]. 
The  specific  mutations  in  NOD2/CARD15 affect the 
LRR–MDP recognition region and disrupt the binding of 
MDP to the NOD2 protein [25]. However, no unifying model 
currently explains the association between NOD2/CARD15 
mutations and CD pathogenesis.
Following the one of hypothesis the proinflammatory 
mediators’  transcription  and  inflammation  induction  even 
under minimal bacterial invasion is explained by that the 
NOD2/CARD15 gene mutations leads to hyperamplification 
in response to MDP stimulation in signal transduction through 
NF-κB [26]. On the over side that is out of this model frames it 
has been demonstrated for today that as minimum the NOD2/
CARD15 gene missense mutations functionally inactivate the 
protein [27]. 
Another theory on CD pathogenesis is that NOD2 
inhibits TLR2-associated signal pathways, thereby inducing 
the synthesis of proinflammatory cytokines such as IL-12 [28]. 
Mutations in NOD2/CARD15 result in the upregulation of 
IL-12, followed by Th1-type adaptive immunity polarization 
[29]. 
Another hypothesis is that NOD2/CARD15 mutations 
lead to not only changes in MDP recognition but also to a 
downregulation  of  α-defensin  production  by  Paneth  cells 
(Fig. 1) [18]. However, patients with CD and NOD2/CARD15 
mutations show a 50% decrease in α-defensin HD5 expression 
[30, 31]. These changes disrupt the homeostasis between the 
macro-organism and bowel microbiota [32]. The decrease in 
the protective potential results in quantitative and qualitative 
alterations in the microbiotic content, with an expansion of 
pathogenic and commensal bacteria, which mediates their 
translocation into the mucosal layer followed by the activation 
of adaptive immunity that primarily involves antigen-
presenting cells (APC) and T-lymphocytes [32, 33].
Current clinical trials have demonstrated that NOD2/
CARD15 gene polymorphisms are associated with early CD 
onset  with  inflammation,  particularly  involving  the  ileum 
(ileitis), as well as the early formation of strictures [34-36].
A previous report has shown that 20%–30% of patients 
with CD harbor NOD2/CARD15 mutations [2]. However, 
the penetrance of these variants is less than 1%; thus, these 
variations can occur even in individuals without CD [37]. 
Therefore,  NOD2/CARD15 mutations are not exclusively 
responsible for CD development. 
Autophagy genes (ATG16L1 and IGRM)
Subsequent investigations in CD genetics have 
implicated autophagy elements [2, 6, 13, 38]. Autophagy is 
a cell mechanism involving excessive or damaged proteins, 
protein complexes, and performing cell organelles utilization 
by cell own lysosomes [39, 40]. Autophagy plays an important 
role in immune protection against viral, bacterial, and 
parasitic infections by selective microorganisms’ utilization 
in lysosomes, called xenophagy [41]. Autophagy also serves 
as an integral link between innate and adaptive immunity, 
providing antigens with major histocompatibility complexes 
class II for the presentation (MHC-II) [42]. 
According to results of some GWAS, single nucleotide 
polymorphisms in ATG16L1  (T300A) are associated with 
high-risk CD development [11, 43, 44]. The ATG16L1 
product is an autophagy modulating protein, ATG16L1, which 
forms a complex with ATG5-ATG12 and is responsible for 
autophagosome formation (Fig. 2) [45]. The role of NOD2 
in autophagy induction in association with ATG16L1 has 
been established, although there is still a need to establish the 
significance between NOD2/CARD15 gene mutations and CD 
pathogenesis [46, 47].
Figure 1.
 Intracellular signal transduction processes associated with 
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In general, ATG16L1 mutations are believed to be 
associated with alterations in xenophagy activation based on 
the recognition of intracellular bacteria patterns by NOD2 
[48]. In addition to the ATG16L1 defects that lead to bowel 
deregulation, Paneth α-defensin exocytosis may also play a 
direct role in CD development [49].
GWAS have identified another autophagy gene, IRGM, 
which has been associated with CD [11, 50]. This gene encodes 
the immunity-related GTPase family M protein (IRGM) [51]. 
The actual function and role of this protein is unknown. It 
has been suggested that IRGM plays a role in protecting the 
cell against intracellular bacteria by inducing autolysosome 
substrate degradation [52]. Defects in autophagy play a 
major role in CD pathogenesis. These defects result in an 
insufficiency in the clearance of pathogens in the GIT and 
interruptions in the activation of adaptive immunity involving 
MHC-II molecule antigen presentation [38]. 
Conclusion
 The last few decades have been marked by major 
breakthroughs in understanding the molecular genetic basis of 
CD. Results of large-scale GWAS have substantially changed 
our view on the pathogenesis of CD. Alterations in innate 
immunity, which influence autophagy and the recognition of 
microbiota structures, appear to be the most important stage 
of CD pathogenesis, followed by the irrational activation of 
adaptive immunity components. 
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